Gavestinel (GV-150526) is a drug which acts as an NMDA antagonist binding selectively to the glycine site on the NMDA receptor complex rather than the glutamate site many NMDA antagonists bind to. It is neuroprotective in animal studies and has been researched for the treatment of stroke progressing as far as Phase II clinical trials in humans before being dropped for lack of efficacy.
This page contains content from the copyrighted Wikipedia article "Gavestinel"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
